Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Götz I, Grosu AL, Spehl TS
Role of PET Imaging in Patients with High-Grade Gliomas undergoing anti-angiogenic Therapy with Bevacizumab – Review of the Literature and Case Report
European Association of NeuroOncology Magazine 2014; 4 (3): 102-108

PDF    Summary    Overview   

This Image - Fig. 1a-d: Glioblastoma Fig. 2a-c: Distant Tumour
Figure/Graphic 1a-d: Glioblastoma
Imaging results of a patient with glioblastoma undergoing bevacizumab therapy. First column: MRI (MP-RAGE with contrast enhancement); second column: 18F-FET-PET (parametric images scaled to mean uptake in a right temporal reference region); third column: image fusion. (A) scan prior to therapy 07/2010; (B) scan after 8 weeks of bevacizumab 09/2010; (C) scan after 16 weeks of bevacizumab 11/2010; (D) scan after re-irradiation with 20 Gy, 01/2011. Bevacizumab therapy was continued. For details, see text
 
Glioblastoma
Previous ImageNext Image   


Figure/Graphic 1a-d: Glioblastoma
Imaging results of a patient with glioblastoma undergoing bevacizumab therapy. First column: MRI (MP-RAGE with contrast enhancement); second column: 18F-FET-PET (parametric images scaled to mean uptake in a right temporal reference region); third column: image fusion. (A) scan prior to therapy 07/2010; (B) scan after 8 weeks of bevacizumab 09/2010; (C) scan after 16 weeks of bevacizumab 11/2010; (D) scan after re-irradiation with 20 Gy, 01/2011. Bevacizumab therapy was continued. For details, see text
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum